chrisvoncsefalvay/vaers-outcomes huggingface dataset:
feeling tired a week after; This spontaneous case was reported by a patient and describes the occurrence of FATIGUE (feeling tired a week after) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical history information was reported.     On 20-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, the patient experienced FATIGUE (feeling tired a week after). At the time of the report, FATIGUE (feeling tired a week after) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided.  No treatment details were reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 27-Jan-2021 and was forwarded to Moderna on 01-Feb-2021.    This spontaneous case was reported by a patient and describes the occurrence of FATIGUE (feeling tired a week after) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical history information was reported.     On 20-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 27-Jan-2021, the patient experienced FATIGUE (feeling tired a week after). At the time of the report, FATIGUE (feeling tired a week after) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant product use was not provided.  No treatment details were reported.
I am in peri-menopause and had not had a menstrual cycle in almost a year.  I starting menstruating  4 days after receiving the booster.  In hindsight, I realize this ALSO happened the last time I got; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 52-year-old female patient (not pregnant) received bnt162b2 omi xbb.1.5 (COMIRNATY (2023-2024 FORMULA)), as dose number unknown (booster), single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history included: "perimenopause" (unspecified if ongoing), notes: had not had a menstrual cycle in almost a year. The patient's concomitant medications were not reported. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE, LOT: HF9275, Vaccine location: Left arm), for COVID-19 immunization; Covid-19 vaccine (DOSE NUMBER UNKNOWN (BOOSTER), SINGLE, MANUFACTURER UNKNOWN), for covid-19 immunization, reaction(s): "Postmenopausal bleeding". The following information was reported: POSTMENOPAUSAL HAEMORRHAGE (medically significant), outcome "unknown", described as "I am in peri-menopause and had not had a menstrual cycle in almost a year.  I starting menstruating  4 days after receiving the booster.  In hindsight, I realize this ALSO happened the last time I got". Therapeutic measures were not taken as a result of postmenopausal haemorrhage.  Clinical course: The patient was in perimenopause and had not had a menstrual cycle in almost a year. She started menstruating 4 days after receiving the booster. In hindsight, she realized this also happened the last time she got a booster shot. Adverse event start date: 21Sep2023. Adverse event start time: 6:00 AM. If AE treatment: No. If other vaccine in four weeks: No. If other medication in two weeks: No.  The information on the batch/lot number for bnt162b2 omi xbb.1.5 has been requested and will be submitted if and when received.
Information has been received from a certified medical assistant (C.M.A) concerning approximately 19 female patients who were vaccinated with 0.5 mL dose of Gardasil (yeast). (Lot # not reported). Subsequently the patient experienced pain at the injection site lasting for about a week. The C.M.A also reported that another patient experienced pain at the injection site lasting for about a week and reported that she almost passed out from the pain (WAES0702USA04000). Attempts are being made to obtain additional identifying information to distinguish the individual patients mentioned in this report. Additional information will be provided if available.  This is in follow-up to report (s) previously submitted on 3/14/2007. Informationhas been received from a certified medical assistant (C.M.A.) concerning a female patient between the ages of 11 to 15 years old who on an unspecified date was vaccinated with a 0.5 mL dose of GARDASIL vaccine, (Lot # not  reported). Subsequently the patient experienced pain at the injection site lasting for about a week. This is one of several reports from the same source. Additional information has been requested.
Felt feverish, chills and weakness.  Arms and left neck swollen and sore. No rash, warmth or edema.  Left supraclavicular area with tender, soft, mobile 3x2 cm mass (most likely lymph node)
12/28/22: admit for myocardial infarction; started on piperacillin-tazobactam for possible aspiration pneumonia, AKI on CKD 01/05/23: pulmonary hemorrhage 01/05/23: ANCA (antineutrophil cytoplasmic antibiotics) vasculitis panel positive 01/08/23: new hematuria 01/09/23: renal biopsy performed, showed atherosclerotic changes but no evidence of ANCA vasculitis, due to limited sample from the renal biopsy ANCA vasculitis cannot be definitively ruled out 01/13/23: patient transitioned to comfort cares
Fever; This spontaneous case was reported by a consumer and describes the occurrence of PYREXIA (Fever) in a 58-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 30-Nov-2021, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced PYREXIA (Fever). At the time of the report, PYREXIA (Fever) outcome was unknown.            No concomitant medication reported. No treatment information was provided.
Patient self pre-medicated with diphenhydramine at 0730 due to reaction from Pfizer 1st COVID vaccination. Today 2/5/2021, 2nd vaccination approximately 0800.  Started to feel chills and numbness/tingling in left arm which was vaccination side.  Then developed numbness/tingling in both legs below the knees.  Placed on pulse oximeter and vitals monitored.  Vital signs normal although initially blood pressure elevated but came back down. ~0830 Patient placed on gurney, covered with warm blankets and given oral medications: diphenhydramine 25mg, famotadine 20mg, acetaminophen 500mg.  At 0930 patient taken to ED as symptoms were not resolving.  Patient had difficulty transferring from gurney to wheelchair for transfer due to leg numbness.
I had a sore throat, runny nose, cough, I had been exposed to COVID-19. I went in the pharmacy to have a PCR COVID-19 test that did come back positive. I will be letting my Primary Care Physician know later today, if I am available to take the Paxlovid I will take it.
Had an allergic reaction which caused the swelling of my lips and eyes. This reaction lasted a little over 24hrs. I went to urgent care where I received steroid shots and Benadryl and was then transferred to ER to be monitored
Information has been received from a health professional concerning 4 elderly patients who on 29-AUG-2006 were vaccinated with a dose of Pneumovax (lot # 651321/1036P). On 29-AUG-2006 the patients developed swelling, redness and heat in their injection site arms. The patients are being treated with BENADRYL and TYLENOL. It was reported that the physician "is very concerned" about the lot number and therefore has requested a lot check. No further information was available. The reporter considered the patient's experiences to be other important medical events. In follow up information the health professional confirmed that the patient had developed swelling, redness and heat in the injection site arm after receiving a dose of Pneumovax 23 (lot # 651321/1036P). She stated that she had no information regarding each patient and stated she was not able to get that information. She said that the doctor had told her that all 4 patients (WAES #'s 0608USA06977, 0609USA05103, and 0609USA05102) had been seen in the office and have since recovered from the swelling, redness and heat in their injection site arms after treatment with BENADRYL and TYLENOL. The health professional was aware that a lot check of concern had been initiated and she stated that she had no further information. The records of testing prior to release of the lot in question have been rechecked and found to be satisfactory. The lot met the requirements of the Office of Biologics Research and Review and was released by the regulatory agency. Additional information is not expected.
Chills; Fever; Body ache; This is a spontaneous report from a contactable consumer, the patient.  A 44-year-old female patient  received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE), via an unspecified route of administration on 03Jan2021 (at the age of 44-year-old) as a single dose for COVID-19 immunization. Medical history included already tested positive for COVID.  There were no concomitant medications. On 04Jan2021 the patient experienced chills, fever, and body ache. Therapeutic measures taken as a result of chills, fever, and body ache included Tylenol 500 mg. The clinical outcome of the events chills, fever, and body ache was unknown.  The lot number for the vaccine, BNT162B2, was not provided and will be requested during follow up.
Pt said she experienced the following reactions: Rash, tremors, nausea, headache, stomach cramping.
pt recvd vax TD vax 2AUG93 got 2.5 ml instead of 0.5ml; the next day devel soreness in the arm of inject, paresthesias in the fingers of the injected arm, severe h/a, & nausea; sx resolved by 5AUG94;
This report described the occurrence of headaches in a female pt who reportedly received Lyme disease vaccine recombinant as part of a clinical trial of compound 215274. This report was received as part of litigation proceedings, and has not been verified by a physician or other health care professional. The pt received injections of LYMErix on 6/8/98, 7/6/98 and 6/3/99 "according to the client." On 9/3/03, the pt's attorney alleged that the pt "suffered from headaches, fatigue, flu-like symptoms, tingling, difficulty concentrating, stomach upset, swollen lymph nodes, muscle and joint pain, and dizziness according to the client." Time to onset from immunization was not reported.
weakness in right hip and leg.  Xray showed no problem. Physical therapy with no good outcome
shingles; This initial spontaneous report was received from a lawyer regarding a case in litigation and refers to a currently 74 year old female patient. No information was provided regarding medical history, concurrent conditions, or concomitant medications. On or around 21-NOV-2012, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) for the long-term prevention of shingles and zoster-related conditions. On an unspecified date, the patient experienced shingles. On an unspecified date, the patient was treated by a physician for shingles. The outcome of the event was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).   Additional information has been requested.
This spontaneous report has been received from a registered nurse, via a company representative, referring to a patient of unknown age and gender. Information about the patient's pertinent medical history, previous drug reactions and allergies and concomitant medication was not provided. On an unknown date, the patient was vaccinated with GARDASIL 9 injection, one dosage form (DF), on an unspecified arm, for prophylaxis (dose number, frequency, route of administration, lot number and expiration date was not provided). The nurse stated that, after the patient was administered the dose of GARDASIL 9, when pulling the needle out of the patient's arm, a few drops leaked out and dripped on the patient's unspecified arm, resulting in possible topical exposure and a possible partial dose. No adverse effects or symptoms were reported.
Vibration (feeling of cell phone vibrating) throughout my entire body, my right jaw has locked and  painful, I have a constant headache, eyesight worse (blurry even with glasses), all over constant body  throbbing, stomach issues (sharp pains and cramping), constant numbness (the feeling of when you rub  your skin when the novocaine is starting to wear off after a dental procedure) from my feet up to my  waist and the feeling of pins and needles (like when you hand is asleep) from my feet up to my pelvic  area. This all started with just a small vibration in my right hip and has increasing gotten worse over the  last several months.
Left arm swollen twice the normal size, inflammation, fever, redness and pain; injection site had purple dime-sized diameter around it. Benadryl and Motrin administered; returned to normal after 2 days of treatment.
hearing loss within a day amongst typical achy...hearing was never regained back after going to numerous doctors and tests performed
On 3/11/10 left arm sore at injection site pt stated no different then previous injections. No redness or swelling. On 3/12 arm soreness improved, then gradually overtime became more uncomfortable. Noticed arm hurts when driving, rolls over in bed, ROM affected. 3/24/10 saw private MD x-ray ordered, apply ice 4 x daily - exercise. NAPROXEN 750 mg BID x 2 wks.
Friday morning, I started to spot/bleeding. Saturday morning, I had heavy bleeding and I am still bleeding. I had a phone call and I have a doctor visit today.  I had a miscarriage.  I'm at the end of it. Tomorrow it should be complete. This is my fifth pregnancy - this is my third miscarriage - I have two children live births. December 6, 2021 - was estimated Date of birth.
Dyssynchronous contraction of IV septum; Elevated IgA; low ferritin; Cardiac MRI showed focal myocardits; Recieved second dose and worsened still/Cardiac MRI showed focal myocardits; ejection fraction down to 33/37% (58% 6 months prior); This is a spontaneous report from a contactable consumer (patient). A 53-year-old female patient (not pregnant) received second dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, Lot Number: ER2613), via an unspecified route of administration, administered in left arm on 22Mar2021 (at the age of 53-year-old) at single dose for COVID-19 immunization. Medical history included previous to vaccine had exposure to A. flavus in 2014 with development of fungal ball in sphenoid cavity causing brain injury from 2014 and all body damage; autonomic disorder developed causing tachycardia. Prior to vaccination, patient was not diagnosed with COVID-19. No known allergy. The patient's concomitant medications were not reported. The patient previously received first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Lot Number: EN6202), administered in left arm on 01Mar2021 (at the age of 53-year-old) at single dose for COVID-19 immunization and developed focal myocarditis, Echo in Nov2020 showed no abnormalities, 12 days after first dose on 13Mar2021 vomited clotted blood, hospitalized, cleared and discharged after a day unknown cause of bleeding, elevated HR and BP, now on ivabradine 2.5mg to lower HR to hope to allow heart to heal; difficulty breathing, chest tightness and extreme fatigue to the point of barely being able to walk continued for several weeks. The patient received second dose and worsened still. After about a month began to normalize. Cardiac MRI on 22Mar2021 showed focal myocardits; ejection fraction down to 33/37% (58% 6 months prior in Sep2020). Dyssynchronous contraction of IV septum not previously present either. Elevated IgA and low ferritin on unspecified dates; awaiting hematologist appt. Events were resulted in Doctor or other healthcare professional office/clinic visit, Emergency room/department or urgent care. Since the vaccination, patient had been tested for COVID-19 which included Nasal swab: Negative on 22Mar2021 and Negative on 10Apr2021. No treatment was received for the events. The outcome of the events was not recovered. Events were reported as serious due to disabling.
The soreness at the injection site was greater than usual and lasted for several days. The patient still feels the soreness if she presses on it. She began to feel intense pain radiating down the arm within a few days and had limited range of motion for months and could not lift or reach with the arm. Has improved - no medical attention sought.
Patient with COPD on 4L of 02 complained of difficulty breathing and S.O.B. Onsite EMS was called vitals HR 104 BP 148/80. EKG presented with abnormal rythm patient was transported to the hospital.
The patient experienced prolonged crying and screaming 3-4 hours. The patient was partially consolable.
Did not dilute Pfizer Covid 19 Vaccine for 5-11 year old vial.  Patient given 0.2ml without being diluted.
Itching; Tiredness; This spontaneous case was reported by a consumer and describes the occurrence of PRURITUS (Itching) and FATIGUE (Tiredness) in an 80-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product IBRUTINIB (IMBRUVICA) capsule for CLL.    Concurrent medical conditions included CLL.   On 10-Sep-2018, the patient started IBRUTINIB (IMBRUVICA) (Oral) 140 milligram three times a day. In February 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. In March 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On 17-Aug-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient experienced PRURITUS (Itching) and FATIGUE (Tiredness). At the time of the report, PRURITUS (Itching) and FATIGUE (Tiredness) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In 2021, SARS-CoV-2 antibody test: (Negative) Negative.         No concomitant medications were reported.   It was unknown if patient was enrolled in a COVID-19 vaccine trial. The reporter's causality for the event(s) of itching and tired with Imbruvica (ibrutinib) was a reasonable possibility. The reporter's causality for the event(s) of not developed antibodies upon covid vaccinations was not provided.  No treatment details were reported.   This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in.
Approximately 24 hours after COVID 19 vaccine administered, started with headache, body aches and chills and fatigue.   Occasional nausea but no vomiting.  Lasted from 1/29/21 to 2/1/21.
REACTION TO COVID BOOSTER SHOT; This spontaneous report received from a consumer via a company representative concerned a female of unspecified age. The patient's height, and weight were not reported. No past medical history or concurrent conditions were reported. The patient previously received covid-19 vaccine ad26.cov2.s (unspecified manufacturer) (Dose number in series 1) (suspension for injection, route of admin not reported, batch number: unknown and expiry: unknown) dose was not reported, 1 total, administered on unspecified date for prophylactic vaccination. The batch number was not reported. The company is unable to perform follow-up to request batch/lot numbers.  It was unknown whether patient had any adverse events following vaccination with first dose of covid-19 vaccine ad26. cov2.s. (Dose number in series 1). The patient received covid-19 vaccine ad26.cov2.s (Dose number in series 2) (suspension for injection, route of admin not reported, batch number: unknown and expiry: unknown) dose, 1 total, administered on an unspecified date for prophylactic vaccination. The batch number was not reported. The Company is unable to perform follow-up to request batch/lot numbers. No concomitant medications were reported.  On an unspecified date, the patient experienced reaction to covid booster shot (Dose number in series 2). The doctor told patient to take Benadryl. The reporter made medical enquiry for dose of children Benadryl Dye-Free. The patient visited physician office for the same event. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The outcome of reaction to covid booster shot was not reported. This report was non-serious.
Within approximately 5 minutes post vaccination during wait period - client c/os dizziness and lightheadedness and pale. Mom carried child to exam table and we placed him in Trendelenburg position, gave cool clothes and a glass of H2O to drink - color returned within minutes, however remained in this position approximately 10 minutes before departure from our facility.
Started seeing black dots, a few dots at first, more dots over time. Sensitivity to sunlight, started mild at first, then got more severe. Started noticing sensitivity to sunlight even on more cloudy days. Formally diagnosed with UVitis. Saw optomologist and retiologist. Taking eye drops 4x a day
loss of balance; Headache; Fatigue; dizziness; nausea; pain in muscles all over body; This is a spontaneous report received from a contactable consumer (patient). A 77-year-old male patient received second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EN6201, expiry date is not reported) via an unspecified route of administration, in Arm Left, on 18-FEB-2021 07:00 AM (at age of 77 years), as a single dose for COVID-19 immunisation. The Patient's medical history included Benign nerve-sheath tumor, not growing. Concomitant medications included Atorvastatin, Tamsulosin, Pepcid, Allegra. Historical vaccine included first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection, lot number: EL3247, expiry date is not reported) via an unspecified route of administration, in Arm Left, on 26-JAN-2021 07:30 AM, as single dose for COVID-19 immunization. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient received Atorvastatin, Tamsulosin, Pepcid, Allegra within 2 weeks of vaccination. The patient was not diagnosed with COVID-19, prior to vaccination. Since the vaccination, the patient has not been tested for COVID-19. The Patient had experienced Headache, fatigue, loss of balance, dizziness, nausea, pain in muscles all over body on 18Feb2021 08:00 PM. Patient didn't receive any treatment for the event. Outcome of the event was reported as Recovered/Resolved with Sequel.
One week following getting the vaccine I had a Meniere's Episode which was by far the worst one I had ever had. Normally the episode will last several hours then I will recuperate within twenty four hours. This time symptoms reoccurred repeatedly and it took five weeks before I started feeling normal again.
Tdap administered 5/24/11 in (R) deltoid. Pain at injection site started at 1900 on 5/24/11. Moderate swelling & redness noted to site 5/25/11. Indiv unable to use raise hand above head. TYLENOL/Ibuprofen for discomfort & cold pack at site.
Fever, chills, diarrhea, migraine headache, chest pains, joint pain, muscle pain, tiredness,  lack of energy. Right arm went numb and immobile due to pain from moving it. Subsided when I woke up approximately 18 hrs later.
Two days after patient's second dose, she discovered large areas of bruising on left leg (from groin to knee) and on left hip.